February 14, 2012Journal of Clinical OncologyOpen Access

Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements

View Full Paper

Ask AI

Bookmark

Abstract

Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kumar et al. (2012) studied this question.

synapsesocial.com/papers/69d5706e75589c71d767dbb3 https://doi.org/10.1200/jco.2011.38.5724

View Full Paper

Ask AI

Bookmark

Abstract

Incorporation of serum FLC-diff into the current staging system improves risk stratification for patients with AL amyloidosis and will help develop risk-adapted therapies for AL amyloidosis.